Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Blood (2024) 144 (Supplement 1): 585.

https://doi.org/10.1182/blood-2024-211449

Published: 2024

Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Blood (2023) 142 (Supplement 1): 631.

https://doi.org/10.1182/blood-2023-178298

Published: 2023

Journal Articles

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Blood (2022) 140 (Supplement 1): 231–233.

https://doi.org/10.1182/blood-2022-170463

Published: 2022

Journal Articles

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Blood (2021) 138 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2021-152167

Published: 2021

Journal Articles

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

Blood (2021) 138 (Supplement 1): 642.

https://doi.org/10.1182/blood-2021-152319

Published: 2021

Journal Articles

Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood- Initial Results of UK NCRI Phase II/III Galactic Trial

Talha Munir, Peter Hillmen, MBChB, PhD, Lucy McParland, Dena Cohen, Anna Hockaday, Jamie Oughton, Fabrizio Messina, David Phillips, Jeffrey R. Neilson, FRCP,FRCPath, Nicholas Pemberton, Shankara Paneesha, MD MRCP, FRCPath, Ben Kennedy, MBChB, FRCP, FRCPath, Andy Rawstron, PhD

Blood (2017) 130 (Supplement 1): 3013.

https://doi.org/10.1182/blood.V130.Suppl_1.3013.3013

Published: 2017

Journal Articles

Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL.

Hazem A. Sayala, Paul Moreton, Ben Kennedy, Guy Lucas, Michael Leach, Saad M.B. Rassam, Andrew Haynes, Jane Tighe, David G. Oscier, Christopher Fegan, Andy C. Rawstron, Peter Hillmen

Blood (2007) 110 (11): 3114.

https://doi.org/10.1182/blood.V110.11.3114.3114

Published: 2007

Journal Articles

Ultrasound Guided Core Biopsy of the Spleen in Lymphoma Diagnosis.

Fiona M. Miall, Adam D. Rye, Kim Krarup, Kevin P. West, W.S.R. Hew, Raman Tyagi, Matthew P.A. Lyttelton, Ben Kennedy, Gillian Thomas, Martin J.S. Dyer

Blood (2007) 110 (11): 4404.

https://doi.org/10.1182/blood.V110.11.4404.4404

Published: 2007

Journal Articles

Enhanced Potency of Glycoengineered Anti-CD52 Monoclonal Antibodies (MAbs).

Martin J.S. Dyer, MD, PhD, Samuel Moser, PhD, Peter Brünker, PhD, Pru Bird, PhD, Neil Almond, PhD, Ursula Püentener, PhD, Luise M.W. Wheat, PhD, Emma Bolam, Eleanor Berrie, PhD, Roger Grau, PhD, Emma Buckby, Ben Kennedy, MD, Richard Stebbings, PhD, Geoff Hale, PhD, Pablo Umana, PhD

Blood (2005) 106 (11): 2958.

https://doi.org/10.1182/blood.V106.11.2958.2958

Published: 2005

Journal Articles

Increasing the Dose Intensity of Alemtuzumab (CAMPATH-1H) in Chronic Lymphocytic Leukemia (CLL): The CAM1515 Study.

Martin J.S. Dyer, MD, PhD, Emma Buckby, Pam Fermahan, Renata Walewska, MD, Ben Kennedy, MD

Blood (2005) 106 (11): 2959.

https://doi.org/10.1182/blood.V106.11.2959.2959

Published: 2005

Journal Articles

No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome

Jeanette Lundin, Ben Kennedy, Claire Dearden, Martin J. S. Dyer, Anders Österborg

Blood (2005) 105 (10): 4148–4149.

https://doi.org/10.1182/blood-2004-11-4314

Published: 2005

Journal Articles

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

Geoff Hale, Peppy Rebello, Lee R. Brettman, Chris Fegan, Ben Kennedy, Eva Kimby, Mike Leach, Jeanette Lundin, Håkan Mellstedt, Paul Moreton, Andy C. Rawstron, Herman Waldmann, Anders Osterborg, Peter Hillmen

Blood (2004) 104 (4): 948–955.

https://doi.org/10.1182/blood-2004-02-0593

Published: 2004

Journal Articles

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia

Andy C. Rawstron, Ben Kennedy, Paul Moreton, Anita J. Dickinson, Matthew J. Cullen, Stephen J. Richards, Andrew S. Jack, Peter Hillmen

Blood (2004) 103 (6): 2027–2031.

https://doi.org/10.1182/blood-2002-10-3270

Published: 2004

Journal Articles

Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion

Andy C. Rawstron, Martin R. Yuille, Julie Fuller, Matthew Cullen, Ben Kennedy, Stephen J. Richards, Andrew S. Jack, Estella Matutes, Daniel Catovsky, Peter Hillmen, Richard S. Houlston

Blood (2002) 100 (7): 2289–2290.

https://doi.org/10.1182/blood-2002-03-0892

Published: 2002

Journal Articles

Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts

Andy C. Rawstron, Michael J. Green, Anita Kuzmicki, Ben Kennedy, James A. L. Fenton, Paul A. S. Evans, Sheila J. M. O'Connor, Stephen J. Richards, Gareth J. Morgan, Andrew S. Jack, Peter Hillmen

Blood (2002) 100 (2): 635–639.

https://doi.org/10.1182/blood.V100.2.635

Published: 2002

Journal Articles

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

Ben Kennedy, Andy Rawstron, Chris Carter, Mary Ryan, Kevin Speed, Guy Lucas, Peter Hillmen

Blood (2002) 99 (6): 2245–2247.

https://doi.org/10.1182/blood.V99.6.2245

Published: 2002

Journal Articles

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

Andy C. Rawstron, Ben Kennedy, Paul A. S. Evans, Faith E. Davies, Stephen J. Richards, Andy P. Haynes, Nigel H. Russell, Geoff Hale, Gareth J. Morgan, Andrew S. Jack, Peter Hillmen

Blood (2001) 98 (1): 29–35.

https://doi.org/10.1182/blood.V98.1.29

Published: 2001

NARROW

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood- Initial Results of UK NCRI Phase II/III Galactic Trial

Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL.

Ultrasound Guided Core Biopsy of the Spleen in Lymphoma Diagnosis.

Enhanced Potency of Glycoengineered Anti-CD52 Monoclonal Antibodies (MAbs).

Increasing the Dose Intensity of Alemtuzumab (CAMPATH-1H) in Chronic Lymphocytic Leukemia (CLL): The CAM1515 Study.

No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia

Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion

Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only